STI Pharmaceuticals Company History

February 2006 STI Pharmaceuticals complete product development trials

STI Pharmaceuticals complete a proof of concept study in 12 healthy volunteers at the University of Bern, Switzerland.  This study confirmed that the cannabinoid combination of Delta-9 Tetrahydrocannabinol (Delta-9 THC)  and Cannabidiol (CBD) are systemically deliverable via an asthma inhaler (pMDI).

The principal investigator, Professor Rudolph Brenneisen, concluded that the inhaler was well tolerated with little evidence of psychotropic activity. 

Further studies are now planned in specific disease groups.

 

 

 

  STI Pharmaceticals  

December 2006
STI Pharmaceuticals appoint Durbin plc to act as UK wholesaler..
more

May 2006
STI Pharmaceuticals supply Dronabinol and Cannabidiol IV preparations to Maudsley Hospital, London..
more

May 2006
STI Pharmaceuticals supply Dronabinol capsules to Hammersmith Hospital, London..
more

April 2006
STI Pharmaceuticals select UK partner to manufacture dosage forms..
more

March 2006
STI Pharmaceuticals granted Home office approval..
more

February 2004
STI Pharmaceuticals win SMART Award..
more